Vistagen announces positive Phase 2A results for PH15 nasal spray improving psychomotor impairment from mental fatigue

Vistagen Therapeutics, Inc.

PH15 nasal spray demonstrated statistically significant improvement in reaction time versus placebo and caffeine (p<0.001) in sleep-deprived participants.
Phase 2A pilot study (2011, acquired via Pherin in February 2023) enrolled 10 participants in a crossover design.
PH15 was safe and well-tolerated; adverse events comparable to placebo, with brief nasal itching in one subject.
CEO Shawn Singh highlighted potential for shift work disorder, sleep apnea, and narcolepsy patients.
No serious adverse events reported; caffeine group experienced palpitations, euphoria, dry mouth, stomachache, and polyuria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.